Expression, purification, and characterization of rhTyrRS
© Lang et al.; licensee BioMed Central Ltd. 2014
Received: 2 March 2014
Accepted: 9 July 2014
Published: 15 July 2014
Aminoacyl-tRNA synthetases (AARSs) catalyze the first step of protein synthesis. Emerging evidence indicates that AARSs may have additional functions, playing a role in signal transduction pathways regulating thrombopoiesis and inflammation. Recombinant human tyrosyl-tRNA synthetase (rhTyrRS) is engineered with a single amino acid substitution that unmasks its cytokine activity. An industrial production method that provides high yield as well as high purity, quality, and potency of this protein is required for preclinical research.
We expressed codon-optimized rhTyrRS in Escherichia coli under fermentation conditions. Soluble protein was purified by a three-step purification method using cation exchange chromatography, gel filtration chromatography, and anion exchange chromatography. We also established a method to test the biological activity of rhTyrRS by measuring aminoacylation and IL-8 release in rhTyrRS-treated HL-60 cells.
The characterization of purified rhTyrRS indicated that this protein can be used in pharmacodynamic and pharmacokinetic studies.
Aminoacyl-tRNA synthetases (AARSs) are enzymes that catalyze the essential first step of protein synthesis by covalently attaching each of the 20 standard amino acids to their cognate tRNA. Because the reactions require the capacity to recognize tRNAs as well as small chemicals such as amino acids and ATP, the structures of AARSs are well equipped for interacting with diverse molecules that may be associated with their functional versatility [1, 2].
AARSs, such as glutamyl-prolyl-tRNA synthetase, glutaminyl-tRNA synthetase, and lysyl-tRNA synthetase, are now known to be multifunctional, participating in a variety of functions including transcription, translation, splicing, inflammation, thrombopoiesis, and apoptosis . Human tyrosyl-tRNA synthetase (TyrRS) was the first example of a tRNA synthetase that played a role in cell signaling and thrombopoiesis. It has been demonstrated that human full-length TyrRS has no known cytokine activity . However, proteolytic removal of the C-domain from TyrRS activates its cytokine function [1, 2, 5]. The N-terminal fragment, named mini-TyrRS, specifically stimulates migration of endothelial cells and polymorphonuclear leukocytes [1, 2, 6, 7]. Mini-TyrRS has also been shown to activate thrombocytopoiesis in a chick chorioallantoic membrane thrombopoiesis assay .
As in some CXC chemokines, such as IL-8, an Glu-Leu-Arg motif embedded in the sequence of mini-TyrRS was shown by mutational analysis to be critical for its cytokine activity [9–11]. Although there is no crystal structure reported for full-length TyrRS, high-resolution crystal structures of mini-TyrRS and of the C-domain enabled reconstruction of the full-length enzyme, and has provided the model and structural basis for its cytokine activity [8, 12]. It is predicted that the C-terminus of the full-length protein is tethered to the N-terminal region, thus preventing ELR substrate recognition [13, 14].
Recombinant human TyrRS (rhTyrRS) is a full-length human tyrosyl-tRNA synthetase with a mutation at Y341A that blocks the H-bond between the ELR motif and Y341. As a result, the ELR motif is exposed, and mini-rhTyrRS-like activity can then promote thrombocytopoiesis [15, 16].
As a potential thrombocytopoietic drug, large-scale expression and purification of rhTyrRS would be desirable. Preclinical testing involving in vitro and animal studies could then be carried out to evaluate its toxic and pharmacologic effects. In this study, rhTyrRS was expressed at a high level in E. coli and purified for future preclinical testing.
Cells and antibodies
The competent E. coli strain BL21 (F-ompT hsdS (rB-mB-) gal dcm; providded by aTyr Pharma) was used as the host for rhTyrRS expression. This strain was transformed with the pET24a inducible expression vector in which the His-tag sequence was deleted and the T7 promoter was replaced with a Tac promoter.
A mouse anti-human IL-8 monoclonal antibody (BC013615, Proteintech Group), rabbit anti-human IL-8 polyclonal antibody (BC013615, Proteintech Group), and goat anti-rabbit IgG-HRP SC-2004 antibody (D2111, Santa Cruz Biotechnology) were used.
A clone with a high rhTyrRS expression level was cultivated in LB agar and M9CA medium (10 g glucose, 6 g Na2HPO4, 35 g KH2PO4, 2.93 g NaCl, 0.4 g NH4Cl, 1.2 g MgSO4, and 1 mL trace element solution per liter). Trace element solution (1 L) consisted of 2.8 g FeSO4 · 7H2O, 2 g MnCl2 · 4H2O, 2.8 g CoSO4 · 7H2O, 1.5 g CaCl2 · 2H2O, 0.2 g CuCl2 · 2H2O, and 0.3 g ZnSO4 · 7H2O. Feeding solutions were 50% glycerol, 250 g/L glucose, and 100 g/L yeast extract. The glucose and MgSO4 solutions were sterilized separately. Kanamycin sulfate was added to a final concentration of 100 μg/mL in both the M9CA and feeding solutions.
Fermentation was performed in a 5-L Bioflo 3000 fermenter (New Brunswick Scientific, New Brunswick, NJ, USA) with automated control of: the pH at 7.0 by the addition of ammonium hydroxide, dissolved O2 at 70% by providing pure oxygen, and agitation at 700 rpm. Air was provided at a flow rate of 4.0 L/min and the temperature was controlled at 30°C. Fermentation was conducted according to the process developed by Shiloach et al. (1996) . The batch phase ends when cells have used up the available glucose. The best indications that the batch phase has ended include a sharp decrease in stirrer speed and an increase in pO2. The bacterial concentration was measured off-line by the optical density at 600 nm and induced with 0.5 mM isopropylthio-β-galactoside (IPTG) once it reached an OD600 of 30 (~10 h). After 6 h of 0.5 mM IPTG induction, the cells were harvested by centrifugation at 6,000 × g for 30 min. The cell pellet was stored at -70°C.
Harvested cell pellets were resuspended in 10 volumes of 20 mmol/L HAc-NaAc buffer (pH 6.0) and subjected to two cycles of microfluidization at 1000 bar. The crude extract was then centrifuged at 10,000 × g for 60 min.
Cation exchange chromatography
The clarified supernatant was loaded onto a SP Sepharose Fast Flow column (GE) that was pre-equilibrated with 20 mmol/L HAc-NaAc buffer (pH 6.0). The bound proteins were eluted with a linear NaCl gradient (0 to 1 mol/L). Fractions containing rhTyrRS were pooled and analyzed by SDS-PAGE.
The pooled fractions were loaded onto a Sephadex-G50 column (GE) pre-equilibrated with 20 mmol/L phosphate buffer (PB; pH 7.0) and rhTyrRS was washed with 20 mmol/L PB at 5 mL/min. Fractions were collected from the column and analyzed by SDS-PAGE.
Anion exchange chromatography
The diluted product solution was loaded onto a 50-mL Q Sepharose Fast Flow column (GE) pre-equilibrated with 20 mmol/L PB (pH 7.0). RhTyrRS was eluted with a linear NaCl gradient (0 to 1 mol/L) and identified by SDS-PAGE via Coomassie blue staining.
SDS-PAGE and sequencing of the N-terminal amino acids
Electrophoresis was carried out in 1-mm-thick gels using BioRad MiniGel apparatus. Coomassie staining was performed as previously described, except that microwave heating was used at each staining step to reduce the total staining and destaining procedure time to 30 min. The protein concentration was measured using BSA as a standard.
The sequence of the N-terminal amino acids of purified rhTyrRS was determined using a protein sequencer (PPSQ-33A, USA).
Proteins resolved in a pre-cast Bis-Tris gel (BioRad) were electrotransferred to a PVDF membrane followed by blocking in 10% BSA solution prepared in TBST (Tris-buffered saline with 0.1% Tween-20). The membrane was then incubated with anti-rhTyrRS monoclonal antibody (1/5000) for 90 min at room temperature. After washing, the membrane was incubated with peroxidase-conjugated goat anti-mouse IgG (1/100,000) for 60 min at room temperature. All antibody incubations and washing steps were carried out in TBST. The immunoreactive bands were visualized with a Western Blot kit (Thermo 34077).
Reversed-phase HPLC was used to study the purity of rhTyrRS. A Higgins Proto 300 C4 column (Waters 150 × 4.6 mm) was used at a flow rate of 1 mL/min and at a temperature of 40°C. The column was eluted with a linear 30-min gradient from 5% B to 95% B (A = 0.1% Trifluoroacetic Acid (TFA) in HPLC water; B = 0.1% TFA in acetonitrile) and monitored by absorbance at 215 nm with a total run time of 40 min.
Mass spectrometry analysis
The purified protein was analyzed by mass spectrometry. Molecular weight measurements were made by LC-MS with a quadrupole-time-of-flight mass spectrometer at the Fudan University Institute of Biomedical Science.
Aminoacylation activity was determined at ambient temperature in 150 mmol/L Tris–HCl (pH 7.5), 150 mmol/L KCl, 10 mmol/L MgCl2, 10 mmol/L β-mercaptoethanol, 4 mmol/L ATP, and 10 mmol/L tyrosine (including 3 mmol/L [3H]-tyrosine, GE Healthcare). Human tRNATyr was prepared as previously described . Before each assay, 100 mmol/L human tRNATyr was annealed by heating at 65°C for 5 min and cooled to room temperature. Reactions were initiated by the addition of rhTyrRS (10 nmol/L) to the reaction mixture. Aliquots were taken at fixed intervals and spotted onto Whatman filter discs saturated with 5% trichloroacetic acid and dried. The filters were placed into ice-cold 5% trichloroacetic acid and washed three times with fresh 5% trichloroacetic acid at 4°C and once with 95% ethanol. The level of tRNA aminoacylation was then quantitated by liquid scintillation counting.
Biological activity assay
RhTyrRS activity was tested using ELISA to measure IL-8 secretion by rhTyrRS-treated HL-60 cells. Cells were thawed from vials and cultured according to the American Type Culture Collection instructions, except that RPMI-1640 (ATCC 30–2001) was supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, formerly Invitrogen 10082–147) and used as growth medium. Cells were plated in a 96-well plate at a density of 1 × 106 cells per 1 mL of medium on the day of the assay. The rhTyrRS was added immediately after cell plating. Cells were plated at 108 μl-1 per well. The protein was diluted in sterile phosphate-buffered saline (PBS; Life Technologies, formerly Invitrogen 10010–023) to a concentration of 10 μmol/L (10× protein stock). The 10× protein stock was serially diluted and 12 μL was added to each well such that the final protein concentrations were 500 nmol/L, 250 nmol/L, 125 nmol/L, 62.5 nmol/L, 31.25 nmol/L, and 15.625 nmol/L. PBS was used as a control. Cells were incubated at 37°C and 5% CO2 for 24 h. The 96-well plate was then spun for 10 min at room temperature in a swinging bucket centrifuge at 1,000 × g. The plate was tilted at a 45° angle and 100 μL of media per well was transferred to a new 96-well plate. The amount of secreted IL-8 protein in the media was then determined by sandwich ELISA.
rhTyrRS expression and purification
The identity of rhTyrRS was verified by Edman degradation to compare the N-terminal sequence of rhTyrRS to the expected mini-TyrRS sequence. Up to 15 amino acids from the N-terminus of rhTyrRS were consistently identical to the reference sequence: Met-Gly-Asp-Ala-Pro-Ser-Pro-Glu-Glu-Lys-Leu-His-Leu-Ile-Trp. We also sought to confirm the identity of rhTyrRS by resolving the sample (s) in parallel with a reference standard by SDS-PAGE followed by western blotting using a polyclonal antibody (Figure 2).
Mass spectrometry analysis
Biological activity assay
Discussion and conclusions
To facilitate the use of rhTyrRS proteins in regulating thrombopoietic activity and to enable structural characterization of this protein, we established a system for the production of large amounts of rhTyrRS. A purity of approximately 97% was routinely achieved with <2% individual contaminants and little to no aggregation.
The final, optimized process consists of cell lysis followed by a sequence of three chromatography steps. The first step (cation exchange) captures rhTyrRS while contaminants flow through, the second step (gel filtration) exchanges the buffer to PB, and the last step (anion exchange) removes the remaining process-related impurities. The final concentration is 1 mg/ml in PBS (pH 7.4). Preliminary characterization of rhTyrRS was performed using western blotting, HPLC, mass spectrometry, and N-terminal sequencing to verify the identity of the protein.
The ability of the purified rhTyrRS to aminoacylate its cognate tRNA molecule was also tested, and analysis of the inherent synthetase activity of rhTyrRS was performed to verify proper protein folding and assess biological activity during the expression and purification processes. Kinetic parameters from different preparations of rhTyrRS will be compared with a well-characterized reference standard. Purification lots that are within the established specifications will be deemed acceptable for release. This assay is still under development but a representative example of the linearity of product accumulation over time is shown below with a range of rhTyrRS concentrations.
The Y341A substitution activated full-length TyrRS for stimulation of cell proliferation. Similar results were observed in an endothelial cell migration assay. In these experiments, wounds were created in monolayers of human umbilical vein endothelial cells . We predict that rhTyrRS not only has IL-8-like cytokine activity, but also can enhance IL-8 production from monocytes . The biological assays of HL-60 stimulation with rhTyrRS presented here demonstrate that this may be the case. The findings presented here will be important for future preclinical studies.
Yongjiang Lang and Yanling Zhang are first author.
We thank aTyr Pharma for providing the plasmid, E. coli strain, and the antibody for rhTyrRS. We really appreciate the advise of Dr. Xianglei Yang and Dr. Paul Schimmel from The Scripps Research Institute. This study was supported by the National Natural Science Foundation of China (NSFC 21242009, NSFCJ121041, JYH6273102/007/016/007), and Science and Technology Commission of Shanghai Municipality (STCSM 10431901000). This study was also supported by The State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University.
- Wakasugi K, Schimmel P: Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science. 1999, 287: 147-151.View ArticleGoogle Scholar
- Wakasugi K, Schimmel P: Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. J Biol Chem. 1999, 274: 23155-23159. 10.1074/jbc.274.33.23155.View ArticleGoogle Scholar
- Yang XL, Kapoor M, Otero FJ, Slike BM, Tsuruta H, Frausto R, Bates A, Ewalt KL, Cheresh DA, Schimmel P: Gain-of-function mutational activation of human tRNA synthetase procytokine. Chem Biol. 2007, 14: 1323-1333. 10.1016/j.chembiol.2007.10.016.View ArticleGoogle Scholar
- Kapoor M, Otero FJ, Slike BM, Ewalt KL, Yang XL: Mutational separation of aminoacylation and cytokine activities of human tyrosyl-tRNA synthetase. Chem Biol. 2009, 16: 531-539. 10.1016/j.chembiol.2009.03.006.View ArticleGoogle Scholar
- Jia J, Li B, Jin Y, Wang D: Expression, purification and characterization of human tyrosyl-tRNA synthetase. Protein Expr Purif. 2003, 27: 104-108. 10.1016/S1046-5928(02)00576-4.View ArticleGoogle Scholar
- Kleeman TA, Wei D, Simpson KL, First EA: Human tyrosyl-tRNA synthetase shares amino acid sequence homology with a putative cytokine. J Biol Chem. 1997, 272: 14420-14425. 10.1074/jbc.272.22.14420.View ArticleGoogle Scholar
- Nangle LA, Zhang W, Xie W, Yang XL, Schimmel P: Char-cot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect. Proc Natl Acad Sci U S A. 2007, 104: 11239-11244. 10.1073/pnas.0705055104.View ArticleGoogle Scholar
- Park SG, Schimmel P, Kim S: Aminoacyl tRNA synthetases and their connections to disease. Proc Natl Acad Sci U S A. 2008, 105: 11043-11049. 10.1073/pnas.0802862105.View ArticleGoogle Scholar
- Yang XL, Guo M, Kapoor M, Ewalt KL, Otero FJ, Skene RJ, McRee DE, Schimmel P: Functional and crystal structure analysis of active site adaptations of a potent anti-angiogenic human tRNA synthetase. Structure. 2007, 15: 793-805. 10.1016/j.str.2007.05.009.View ArticleGoogle Scholar
- Wakasugi K, Slike BM, Hood J, Otani A, Ewalt KL, Friedlander M, Cheresh DA, Schimmel P: A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci U S A. 2002, 99: 173-177. 10.1073/pnas.012602099.View ArticleGoogle Scholar
- Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen L, Hartlein M, Kron M, Yang D, Yiadom K, Dwivedi S, Plotz PH, Oppenheim JJ: Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells.J. Exp Med. 2002, 196: 781-791. 10.1084/jem.20020186.View ArticleGoogle Scholar
- Liu J, Yang XL, Ewalt KL, Schimmel P: Mutational switchingof a yeast tRNA synthetase into a mammalian-like synthetase cytokine. Biochemistry. 2002, 41: 14232-14237. 10.1021/bi0205395.View ArticleGoogle Scholar
- Yang XL, Schimmel P, Ewalt KL: Relationship of two human tRNA synthetases used in cell signaling. Trends Biochem Sci. 2004, 29: 250-256. 10.1016/j.tibs.2004.03.002.View ArticleGoogle Scholar
- Yang XL, Liu J, Skene RJ, McRee DE, Schimmel P: Crystal structure of an EMAP-II-like cytokine released froma human tRNA synthetase. Helv Chim Acta. 2003, 86: 1246-1257. 10.1002/hlca.200390107.View ArticleGoogle Scholar
- Yang XL, Otero FJ, Skene RJ, McRee DE, Schimmel P, Ribas de Pouplana L: Crystal structures that suggest late development ofgenetic code components for differentiating aromatic side chains. Proc Natl Acad Sci U S A. 2003, 100: 15376-15380. 10.1073/pnas.2136794100.View ArticleGoogle Scholar
- Curtis BM, Williams DE, Broxmeyer HE, Dunn J, Farrah T, Jeffery E, Clevenger W, deRoos P, Martin U, Friend D: Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. Proc Natl Acad Sci U S A. 1991, 88: 5809-5813. 10.1073/pnas.88.13.5809.View ArticleGoogle Scholar
- Shiloach J, Kaufman J, Guillard AS, Fass R: Effect of glucose supply strategy on acetate accumulation, growth, and recombinant protein production by Escherichia coli BL21 (λDE3) and Escherichia coli JM109. Biotechnol Bioeng. 1996, 49: 421-428.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.